Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas, is recalling ten lots of compounded glutathione injection nationwide because of potentially elevated endotoxin levels. The company says it has received two reports of patients who needed emergency department care after a glutathione product was given intravenously, although the product was not formulated for IV use. … Read more
Three physicians at the University of Missouri-Kansas City and Saint Luke’s Mid America Heart Institute have published a review that does something the injectable-peptide market rarely gets: a compound-by-compound account of what is claimed, what mechanism is proposed, and what could go wrong. It covers BPC-157, TB-500, CJC-1295 and ipamorelin, MK-677, melanotan-II, GHK-Cu, retatrutide and … Read more
On September 18, 2026, the FDA issued a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, of Houston, Texas, following an inspection of its facility in November 2025. The agency said the pharmacy compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products that appear to be essentially copies of FDA-approved drugs — the legal line … Read more
Nine people reported fever, chills, chest pain or vomiting after receiving compounded injections that a Houston pharmacy has now recalled nationwide. Centric Compounding is pulling six lots of glutathione, Myer’s Cocktail and Tri-Immune Boost, injectables sold to support immunity, fatigue and general wellness, after the glutathione raw ingredient used to make them was found to … Read more
The FDA extended the comment period on its 1 May proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. Comments were originally due 30 June 2026; the deadline moved to 30 July 2026. Sources: Federal Register 2026-12937
The FDA issued a further round of warning letters on 8 June 2026, including to Altru Telehealth, Medica Weight Loss and FITISH, continuing the enforcement line it opened in September 2025 and widened in March 2026. Sources: Altru Telehealth · Medica Weight Loss · FITISH
The FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list — the roster of substances outsourcing facilities may legally compound from bulk. The agency stated it had reviewed the nominations it received and did not find sufficient evidence of a clinical need for any of the three. If finalised, the … Read more
The FDA restated the conditions a compounded drug must meet to qualify for the section 503A and 503B exemptions, and addressed a practice common in compounded GLP-1 products directly. It said a product combining semaglutide with another active ingredient, giving vitamin B12 (cyanocobalamin) as its example, may still be considered essentially a copy of a … Read more